ジプレキサ錠２．５ｍｇ
基本情報
| 項目 | 値 |
|---|---|
| DrugBank ID | DB00334 |
| エビデンスレベル | L5（計算予測のみ） |
| 予測適応症数 | 50 |
| 日本商品名（例） | オランザピン細粒１％「アメル」, オランザピン細粒１％「サワイ」, オランザピン細粒１％「タカタ」 |
承認適応症（KEGG）
統合失調症、双極性障害
予測適応症（TxGNN）
以下は TxGNN モデルにより予測された潜在的新適応症です。スコアが高いほど関連性が高いと予測されています。
| # | 適応症 | スコア | ソース |
|---|---|---|---|
| 1 | manic bipolar affective disorder | 99% | DL |
| 2 | major depressive disorder | 99% | DL |
| 3 | anxiety disorder | 99% | DL |
| 4 | endogenous depression | 99% | DL |
| 5 | bipolar disorder | 99% | DL |
| 6 | benign paroxysmal torticollis of infancy | 99% | DL |
| 7 | agoraphobia | 99% | DL |
| 8 | major affective disorder | 99% | DL |
| 9 | schizophrenia | 99% | DL |
| 10 | dysthymic disorder | 99% | DL |
| 11 | unipolar depression | 98% | DL |
| 12 | distal 17p13.3 microdeletion syndrome | 98% | DL |
| 13 | neurotic disorder | 98% | DL |
| 14 | neurotic depression | 98% | DL |
| 15 | melancholia | 98% | DL |
| 16 | retinal dystrophy with or without extraocular anomalies | 98% | DL |
| 17 | Ohdo syndrome and variants | 98% | DL |
| 18 | childhood apraxia of speech | 98% | DL |
| 19 | congenital disorder of glycosylation with defective fucosylation | 98% | DL |
| 20 | hydranencephaly (disease) | 98% | DL |
| 21 | phobic disorder | 98% | DL |
| 22 | syndromic myopia | 98% | DL |
| 23 | Malan overgrowth syndrome | 98% | DL |
| 24 | myopia X-linked | 98% | DL |
| 25 | Keppen-Lubinsky syndrome | 98% | DL |
| 26 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 98% | DL |
| 27 | Charcot-Marie-Tooth disease, demyelinating, type 1G | 98% | DL |
| 28 | blepharophimosis - intellectual disability syndrome, Ohdo type | 98% | DL |
| 29 | myopia 26, X-linked, female-limited | 98% | DL |
| 30 | hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome | 97% | DL |
| 31 | atypical glycine encephalopathy | 97% | DL |
| 32 | surfactant metabolism dysfunction, pulmonary | 97% | DL |
| 33 | congenital isolated adrenocorticotropic hormone deficiency (disease) | 97% | DL |
| 34 | autosomal dominant slowed nerve conduction velocity | 97% | DL |
| 35 | ligneous conjunctivitis | 97% | DL |
| 36 | trichotillomania | 97% | DL |
| 37 | vitamin B12-responsive methylmalonic acidemia | 96% | DL |
| 38 | gaze palsy, familial horizontal, with progressive scoliosis | 96% | DL |
| 39 | autism spectrum disorder | 96% | DL |
| 40 | Phelan-McDermid syndrome | 96% | DL |
| 41 | chromosome 15q26-qter deletion syndrome | 96% | DL |
| 42 | mixed anxiety and depressive disorder | 96% | DL |
| 43 | asperger syndrome, susceptibility to | 96% | DL |
| 44 | autism susceptibility 1 | 95% | DL |
| 45 | chromosome 2P16.3 deletion syndrome | 94% | DL |
| 46 | Tourette syndrome | 94% | DL |
| 47 | Pitt-Hopkins-like syndrome 2 | 93% | DL |
| 48 | amelocerebrohypohidrotic syndrome | 92% | DL |
| 49 | familial hypertryptophanemia | 92% | DL |
| 50 | obsessive-compulsive disorder | 92% | DL |
免責事項
これらの予測は研究目的のみであり、医療アドバイスを構成するものではありません。 臨床応用には必ず適切な検証が必要です。